الفهرس | Only 14 pages are availabe for public view |
Abstract CD64 [Fc gamma receptor 1 (FcγRI)] & HLA-DR is an MHC class II molecule tested as biomarkers used in predicting severe bacterial infection. The study was designed to assess their level in ICU patients with liver cirrhosis as a possible biomarker of inflammation. A case-control study was conducted, 70 patients with liver cirrhosis (35 with sepsis & 35 without sepsis), 30 healthy individuals as a control group. Laboratory and imaging studies were evaluated. The levels of CD64, HLA-DR expressions in peripheral blood and Sepsis Index were measured for all patients by flowcytometry using fluorescein isothiocyanate (FITC)-conjugated anti-CD64 monoclonal antibody and (FITC) Anti-Human HLA-DR Antibody. The levels of CD64, HLA-DR and SI in peripheral blood have higher statistically significant in sepsis compared to control group with P Value (PMN CD64% 0.001, PMN CD64 MFI 0.001, PMN HLA-DR% 0.001, Monocyte CD64% 0.003, Monocyte CD64 MFI 0.001, Monocyte HLA-DR MFI 0.002 and SI 0.001). Although, the levels of CD64 expressions in peripheral blood, HLA-DR and Sepsis index have no statistically significance in sepsis in liver cirrhotic patients and patients without sepsis except (highly statistically significance Monocyte CD64% 0.003 & statistically significance Monocyte CD64 MFI 0.030). Also, in cirrhotic patients with sepsis ALBI score and S.Lactate level showed highly statistically significance wit P Value (0.017 and 0.001). The levels of Monocyte CD64% and Monocyte CD64 MFI expressions in peripheral blood are considered good biomarkers of sepsis in liver cirrhosis. Also, ALBI score and S.Lactate level are considered good indicator for sepsis in patients with liver cirrhosis. |